

Manuscript No. 63080

The risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

Reviewer #1: Scientific Quality: Grade A (Excellent)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: Title: I will rather remove from the title "literature review" - it does not add valuable information (if not systematic) and should be avoided. Keywords: should ideally be taken from the MeSH browser. Overall, very, very good manuscript written in a good manner reflecting the evidence-based approach towards patients with AID and hep B. Finally, thanks for the opportunity to review, it was an interesting reading.

Response: We appreciate this important suggestion. We removed "literature review" in the title and used keywords which are available on MeSH browser.

Reviewer #2: Scientific Quality: Grade A (Excellent)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: Very good presentation. The topics of this review article are absolutely to the point without useless reports. The messages are clear and the quality of the figure is high. The list of references is complete and updated.

Response: Thank you for this comment.

Reviewer #3: Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: The use of immunosuppressive drugs and the specific targeting of inflammatory cytokines in autoimmune diseases can lead to the spread of various infections, including viruses. This is why the proper use of immunosuppressive drugs and cytokine-targeted therapies has always been discussed. This study has been reviewed the risk of HBVr in patients with autoimmune diseases undergoing TNF or non-TNF inhibitors to characterize risk of HBVr in patients treated with non-TNF-targeted biologics. Considering that similar studies of this study have been done in the past, the advantages and innovations of this study compared to previous studies should be mentioned.

Response: We appreciate this comment. We have reviewed previous literatures and did not find any review articles similar to our study reviewing the risk of HBV reactivation in patients with autoimmune diseases who are treated with non-TNF antagonists. Hence, we believed that our review article has high originality and advantages.